2013 looks set to be another great year for generics and biosimilars, with once again some major blockbuster drugs losing patent protection. Just looking at just five of the best-selling drugs, US sales of more than US$14 billion will be open to competition by the generics and biosimilars industry.
Key patent expiries in the US—according to data from market research firm IMS Health— include painkiller oxycontin (oxycodone), cancer treatment Zometa (zoledronic acid) and acid reflux treatment Aciphex (rabeprazole). These patent expiries can mean a major blow to some of the largest pharmaceutical companies, whilst it will be very good news for the generics and biosimilars industry and patients.
Table 1: Key patent expiries during 2013 in the US
*combined sales with Neulasta (pegfilgrastim)
GERD: gastroesophageal reflux disease; neutropenia: a lack of certain white blood cells caused by cancer Sources: IMS Market Prognosis, April 2011, Reuters, Verispan, VONA Two of Amgen’s blockbuster biologicals are included in the list of drugs set to lose patent protection in 2013. The company’s treatment for low white blood cells, Neupogen (filgrastim), and its cancer-induced anaemia treatment, Epogen (epoetin alfa), will both lose their patent protection in the US in 2013, by which time the FDA should hopefully have sorted out practical biosimilars guidelines. These two biologicals have already lost patent protection in Europe, where biosimilars for epoetin alfa were already introduced in 2007 and for filgrastim in 2008 .
Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.No tags for this post.